References:

1. Maravelias C, Dona A, et al. Adverse effects of anabolic steroids in athletes: A constant threat. Toxicol Letters 2005;158:167-175.

2. Thompson PD, Cullinane EM, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989;261:1165-8.

3. Stimac D, Milić S, et al. Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002;35:350-2.

4. Catlin DH, Ahrens BD, et al. Detection of norbolethone, an anabolic steroid never marketed, in athletes' urine. Rapid Commun Mass Spectrom 2002;16:1273-5.

5. Malvey TC, Armsey TD 2nd. Tetrahydrogestrinone: the discovery of a designer steroid. Curr Sports Med Rep 2005;4:227-30.

6. Friedel A, Geyer H, et al. Tetrahydrogestrinone is a potent but unselective binding steroid and affects glucocorticoid signalling in the liver. Toxicol Lett 2006;164:16-23.

7. Bagchus WM, Smeets JM, et al. Pharmacokinetic evaluation of three different intramuscular doses of nandrolone decanoate: analysis of serum and urine samples in healthy men. J Clin Endocrinol Metab 2005;90:2624-30.

8. Attardi BJ, Page ST, et al. Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities. J Steroid Biochem Mol Biol 2010;118:151-61.

9. Kamanga-Sollo E, White ME, et al. Effect of trenbolone acetate on protein synthesis and degradation rates in fused bovine satellite cell cultures. Domest Anim Endocrinol 2011;40:60-6.

10. Anonymous. The LAWS OF TRENBOLONE. http://www.musclechemistry.com/upload/anabolic-discussion-forum/65591-laws-trenbolone.html, accessed March 16, 2015.

11. Venetikou MS, Lambou T, et al. Hyperprolactinaemia due to hypothalamic-pituitary disease or drug-induced in patients with erectile dysfunction. Andrologia 2008;40:240-4.

12. Donner DG, Beck BR, et al. Improvements in body composition, cardiometabolic risk factors and insulin sensitivity with trenbolone in normogonadic rats. Steroids 2015;94:60-9.

13. Reagan-Shaw S, Nihal M, et al. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61.

14. Yarrow JF, McCoy SC, et al. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids 2010;75:377-89.

15. Ma F, Liu D. 17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration. Toxicol Appl Pharmacol 2015;282:68-76.